Lovastatin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Hyperlipidaemias, Primary prophylaxis of coronary artery disease
Adult: Initially, 10-20 mg/day in the evening, may increase at intervals of at least 4 wk to max 80 mg/day as a single or in 2 divided doses.
Child: As an adjunct w/ heterozygous familial hypercholesterolaemia: 10-17 yr Initially, 10-20 mg once daily, may increase at intervals of 4 wk to max 40 mg once daily.
Renal impairment:
CrCl (ml/min)Dosage Recommendation
<30Use w/ caution in doses >20 mg/day.
Administration
Should be taken with food.
Contraindications
Active liver disease or unexplained persistent elevated serum transaminases. Concomitant use w/ CYP3A4 inhibitors (e.g. nefazodone, erythromycin, boceprevir, clarithromycin, telithromycin, HIV protease inhibitors, itraconazole, ketoconazole, posaconazole, telaprevir), gemfibrozil, ciclosporin. Pregnancy and lactation.
Special Precautions
History of liver disease; patients at risk of myopathy; alcoholism; inadequately controlled hypothyroidism. Severe renal impairment. Monitoring Parameters Monitor creatine kinase (CK) periodically and LFT. Discontinue if there is significant or persistent increase in CK levels, serum aminotransferase levels or evidence of myopathy.
Adverse Reactions
GI disturbances, headache, dizziness, insomnia, myopathy or rhabdomyolysis (dose related), myalgia, arthralgia, wt gain, blurred vision, rash, asymptomatic hepatic aminotransferase elevation.
Potentially Fatal: Severe rhabdomyolysis w/ acute renal failure. Hepatitis, pancreatitis. Rare: Stevens-Johnson syndrome, anaphylaxis, toxic epidermal necrolysis.
Drug Interactions
Increased risk of myopathy/rhabdomyolysis w/ amiodarone, colchicine, ranolazine, danazol, diltiazem and verapamil. May increase anticoagulant effect of warfarin.
Potentially Fatal: Increased risk of myopathy and rhabdomyolysis w/ concomitant CYP3A4 inhibitors (e.g. nefazodone, erythromycin, boceprevir, clarithromycin, telithromycin, HIV protease inhibitors, itraconazole, ketoconazole, posaconazole, telaprevir), gemfibrozil, ciclosporin.
Food Interaction
Reduced serum levels w/ St John's wort. Increased serum level w/ grapefruit juice, avoid concurrent intake of >1 quart/day.
Lab Interference
May alter thyroid function tests.
Action
Lovastatin reduces cholesterol by competitively inhibiting HMG-CoA reductase, the rate-limiting step cholesterol biosynthesis.
Absorption: 30% absorbed from the GI tract. Time to peak plasma concentration: W/in 2-4 hr.
Distribution: <5% reach the circulation. Plasma protein binding: >95%.
Metabolism: Extensively hepatic via hydrolysis; converted to active β-hydroxyacid form.
Excretion: Via faeces (approx 85%); via urine (approx 10%). Elimination half-life: 1-2 hr.
Storage
Oral: Store between 20-25°C.
ATC Classification
C10AA02 - lovastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Disclaimer: This information is independently developed by CIMS based on lovastatin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in